MICA · FIRST-LINE LEARNING NOTES
Understand, prioritise and organise follow-up
Safe corticosteroid use combines a documented indication, complication prevention and a follow-up, tapering and intercurrent-illness plan tailored to actual exposure.
Clarify indication and exposure
Record the condition, treatment goal, anticipated duration and responsible clinician. Include tablets, inhalers, injections, topical products and repeated courses. Systemic effects are not limited to oral treatment. Review disease activity separately from adverse effects so that corticosteroids are not continued without a clear clinical objective.
[1][2]Plan initial prevention
According to exposure and patient risk, assess diabetes or hyperglycaemia risk, hypertension, fracture risk, visual problems, infection and mental health vulnerability. Arrange appropriate bone protection and monitoring. Review vaccination and concomitant medicines, particularly NSAIDs. Baseline investigations and repeat testing are individualised; one identical panel is not required for every short course.
[3][2]During dose reduction, distinguish recurrence of the treated disease, withdrawal symptoms and adrenal insufficiency. Risk depends on duration, dose, medicines and exposure through other routes, including inhaled or injected preparations. Tapering requires assessment of disease control and tolerance rather than reliance on a calendar alone.
[1][3]Make tapering and emergency care safer
Following prolonged exposure, do not abruptly discontinue treatment without a medical plan. Fatigue, pain or malaise during reduction may represent relapse, withdrawal or adrenal insufficiency and require assessment. The 2024 ESE/Endocrine Society guideline adapts tapering to disease control and adrenal risk. One fixed taper does not suit every patient.
[1]- Avoid abrupt discontinuation after potentially suppressive exposure; coordinate tapering with the prescribing team.
- Advise at-risk patients about acute illness management and identification of their steroid treatment.
- During withdrawal, assess unusual fatigue, vomiting or hypotension rather than automatically attributing symptoms to the original disease.
Provide practical follow-up instructions
Monitor response, weight, blood pressure, glucose and other indicated measures. Ask about insomnia, mood changes, infection, bone and eye symptoms. Patients at adrenal risk need written plans for acute illness, procedures and inability to take oral treatment. Prolonged vomiting, hypotension or altered consciousness in this setting requires emergency assessment rather than routine follow-up.
[1][3][4]A learning situation
FICTIONAL CASE · SELF-REFLECTION WITHOUT A SCORE
A patient on long-term treatment for an inflammatory condition is following a prescribed steroid taper. Gastroenteritis prevents retention of tablets; profound weakness and faintness develop.
Should care wait for the next cortisol test?
Read the reasoning
No. Inability to retain treatment and faintness raise concern for adrenal crisis and dehydration. Urgent assessment and the appropriate emergency protocol are needed. Anticipating this situation with an individual written plan is preferable to an improvised, unsupervised dose change.
References and scope
- European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency ↗
- Steroids ↗
- Corticosteroids monitoring ↗
- Information for Individuals on Glucocorticoid (Steroid) Therapy ↗
Original educational synthesis for adult first-line practice. International references must be interpreted with the clinical setting and local care pathways. Independent human scientific review remains to be confirmed.